GGrantIndex
← Search

PHASE III TRIAL OF TAMOXIFEN VS TAMOXIFEN PLUS RT FOR RISK DUCT CARCINOMA

$9,707M01FY2005RRNIH

Children'S Research Institute, Washington DC

Investigators

Linked publications & trials

View original record on NIH RePORTER →